Design Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DSGN Nasdaq 2836 www.designtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Design Therapeutics, Inc.

Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference - May 28th, 2026 6:00 am
This Biotech Leader Ran Up As Much As 18% — And Then Lost It All - May 18th, 2026 2:07 pm
Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN) - May 18th, 2026 8:02 am
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia - May 18th, 2026 5:00 am
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026 - May 17th, 2026 2:00 pm
Jim Cramer on Design Therapeutics: “Pure Spec, Pure Spec” - May 17th, 2026 7:12 am
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know - May 11th, 2026 10:00 am
Design Therapeutics Inc (DSGN) Q1 2026 Earnings Call Highlights: Promising Progress in ... - Apr 29th, 2026 5:00 pm
Design Therapeutics Q1 Earnings Call Highlights - Apr 29th, 2026 3:04 am
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates - Apr 28th, 2026 2:01 pm
We Think Design Therapeutics (NASDAQ:DSGN) Can Afford To Drive Business Growth - Apr 11th, 2026 8:05 am
Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program - Mar 15th, 2026 7:39 am
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates - Mar 9th, 2026 2:01 pm
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference - Feb 26th, 2026 3:53 am
Design Therapeutics to Participate in Upcoming Investor Conferences - Feb 18th, 2026 6:00 am
Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says - Nov 20th, 2025 9:48 am
Here Are Thursday’s Top Wall Street Analyst Research Calls: AON, Apollo Global, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA, and More - Nov 20th, 2025 7:21 am
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results - Nov 5th, 2025 2:01 pm
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans - Nov 2nd, 2025 5:00 am
Design Therapeutics Appoints Justin Gover to Board of Directors - Sep 10th, 2025 2:01 pm